As of 2024-12-13, the Relative Valuation of Denali Therapeutics Inc (DNLI) is (80.79) USD. This relative valuation is based on P/E multiples. With the latest stock price at 23.47 USD, the upside of Denali Therapeutics Inc based on Relative Valuation is -444.2%.
The range of the Relative Valuation is (82.81) - (90.89) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 27.9x - 44.6x | 34.8x |
| Forward P/E multiples | 19.6x - 30.6x | 19.6x |
| Fair Price | (82.81) - (90.89) | (80.79) |
| Upside | -452.8% - -487.3% | -444.2% |
| Date | P/E |
| 2024-11-29 | -8.42 |
| 2024-11-27 | -8.47 |
| 2024-11-26 | -8.31 |
| 2024-11-25 | -8.25 |
| 2024-11-22 | -8.31 |
| 2024-11-21 | -8.15 |
| 2024-11-20 | -8.22 |
| 2024-11-19 | -8.19 |
| 2024-11-18 | -8.14 |
| 2024-11-15 | -8.43 |
| 2024-11-14 | -9.58 |
| 2024-11-13 | -9.98 |
| 2024-11-12 | -10.06 |
| 2024-11-11 | -10.63 |
| 2024-11-08 | -10.55 |
| 2024-11-07 | -9.97 |
| 2024-11-06 | -9.95 |
| 2024-11-05 | -9.31 |
| 2024-11-04 | -9.16 |
| 2024-11-01 | -9.11 |
| 2024-10-31 | -8.74 |
| 2024-10-30 | -9.04 |
| 2024-10-29 | -9.25 |
| 2024-10-28 | -9.35 |
| 2024-10-25 | -8.80 |
| 2024-10-24 | -8.90 |
| 2024-10-23 | -8.78 |
| 2024-10-22 | -8.85 |
| 2024-10-21 | -8.88 |
| 2024-10-18 | -9.29 |
| 2024-10-17 | -9.23 |
| 2024-10-16 | -9.31 |
| 2024-10-15 | -9.04 |
| 2024-10-14 | -9.03 |
| 2024-10-11 | -9.43 |
| 2024-10-10 | -8.67 |
| 2024-10-09 | -8.93 |
| 2024-10-08 | -9.00 |
| 2024-10-07 | -8.96 |
| 2024-10-04 | -9.64 |
| 2024-10-03 | -9.50 |
| 2024-10-02 | -9.77 |
| 2024-10-01 | -9.65 |
| 2024-09-30 | -9.81 |
| 2024-09-27 | -9.91 |
| 2024-09-26 | -9.85 |
| 2024-09-25 | -9.76 |
| 2024-09-24 | -10.21 |
| 2024-09-23 | -10.18 |
| 2024-09-20 | -10.41 |